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Occurrence of large-scale mitochondrial DNA deletions
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A b s t r a c t
Introduction: The aim of this study was to determine the mutation patterns of
colon cancers through screening of different regions of mitochondrial DNA
(mtDNA) in colon cancer patients.
Material and methods: In order to investigate whether deletions exist in the
mitochondrial DNA of colon cancer patients, we used a PCR assay to assess the
presence of large-scale deletions. We screened four regions of the mitochondrial
genome by PCR amplification and Southern blot analysis followed by DNA
sequencing. Previously, deficiency in mitochondrial complex I has been reported;
therefore we focused on the region of mtDNA that encodes the genes of this complex. 
Results: In 11 out of 90 patients, we found an 8.7 kb deletion. Large-scale deletions
of mtDNA are common events that have been found to occur in human ageing
and in patients with mitochondrial myopathies. Based on our results the mtDNA 
8.7 kb deletion occurs in 12.2% of the colorectal cancer (CRC) samples.
Conclusions: As reactive oxygen species (ROS) are continuously generated by the
respiratory chain, they may cause significant oxidative damage to mtDNA (for
example mtDNA deletions or mutations) if not efficiently eliminated. Defective
respiratory enzymes containing protein subunits encoded by the deleted mtDNA
may further enhance free radical production, resulting in more profound oxidative
damage in CRC patients. 
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Introduction
Colorectal cancer is one of the most common human malignancies in
both genders. It is the third most common cause of cancer-related deaths
in the world [1].
It has been reported that mitochondrial DNA (mtDNA) is more
susceptible to mutation than nuclear DNA (nDNA) [1, 2] and is frequently
mutated in different types of cancers [3-14], including 10 to 70% of
colorectal carcinomas [3, 5, 15-18]. These findings suggest a potential role
of the mitochondrial genome in tumour carcinogenesis.
Mitochondria are cytoplasmic organelles that generate energy in the form
of ATP through oxidative phosphorylation (OXPHOS) [19]. Human mtDNA 
is a double stranded circular molecule of 16,569 nucleotides and contains 
37 genes coding for two rRNAs, 22 tRNAs and 13 polypeptides. The copy
number of mtDNA is around 103–104 per cell and the vast majority of copies
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are identical at birth. Furthermore, mtDNA is known
for having a high acquired mutation rate which is 
10 times higher than that of nuclear genomic DNA. It
is generally accepted that the high mutation rate of
mtDNA is caused by lack of protective histones,
inefficient DNA repair systems and continuous expo-
sure to mutagenic effects of oxygen radicals gene-
rated by OXPHOS [20]. Mutations in mtDNA have
been reported to occur in human cancers [21-26].
Material and methods
Control subjects and patients
A total of 90 blood samples of CRC patients were
collected from the Department of Oncology,
Sayedoalshohadae hospital in Isfahan (Iran). The
patients consisted of 46 women and 44 men ranging
in age from 26 to 78 years (mean age 54.8 years). All
of them had well differentiated adenocarcinomas.
Demographic, clinical and tumour-related characte-
ristics of patients were recorded based on their
hospital documents. These parameters included
gender, age at diagnosis, place and date of birth and
tumour-related factors such as location, stage, degree
of differentiation and mucus production.
All of these patients were interviewed to trace
their family history of cancer including occurrence
of malignancy in the family, type of cancer and the
age at diagnosis of the affected family member.
In the families of fifteen patients we saw occur-
rence of malignancy but only one case had colon
cancer history in his family.
The control group consisted of 33 Iranian people
(14 men and 19 women; mean age 37.5 years), who
visited the blood donor clinic in Tehran. They
answered an extensive questionnaire regarding their
current health and medical history, and we chose
healthy individuals with neither apparent genetic or
metabolic disorders nor any type of cancer.
DNA extraction
Total DNA was isolated according to standard
methods (DNAfast, Genfanavaran, Tehran, Iran).
Multiplex PCR
Multiplex PCR was carried out using five sets of
primers: PD1/PD2, PD1/PD5, PD3/PD4, PD5/PD3 and
PD6/PD3 (Figure 1). PD1 primer (5’-GAACATACAAAA
CCCACCCC-3’) located at 5421–5440 bp and PD2
primer (5’-GGCGGGAGAAGTAGATTGAA-3’) located
at 5740-5721 bp of the mtDNA were used to amplify 
a 319 bp fragment in a rarely deleted region as an
internal control in each sample. PD1 primer and 
PD5 primer (5’-TTGGCGTGAAGGTAGCGGAT-3’) lo-
cated at 15000–14981 bp were used to amplify an
850 bp region created by the 8.7 kb deletion. PD3
primer (5’-CTACGGTCAATGCTCTGAAA-3’) located at
8161–8180 bp and PD4 primer (5’-GGTTGACCTGTTA-
GGGTGAG-3’) located at 13640–13621 bp of the
mtDNA were used to amplify the region created by
the 5 kb deletion. PD1 primer and PD4 primer, PD3
primer and PD6 primer (5’-GTGGTCAAGTATTTATG-
GTA-3’) located at 16150–16131 bp were used to
amplify regions created by 7.5 kb and 7.4 kb deletions. 
Southern blot analysis
Genomic DNA was digested overnight with
BamHI and was electrophoresed on 0.6% agarose
gel. After electrophoresis, DNA was denatured,
neutralized and transferred to positively charged
nylon membranes. Meanwhile, mt15340F primer
(5’-ATTCTTGCACGAAACGGGATC-3’) located at
15340-15360 bp and mt91R primer (5’-GCTCCGGCT-
CCAGCGTCTCG-3’) located at 110-91 bp of the
mtDNA were used to amplify 1339 bp fragment
from the D-loop region. This fragment was used as
an mtDNA probe for Southern blotting. Southern
blot analysis was performed using DIG DNA Labeling
and Detection Kit (Cat. #11093657910, Roche
Penzberg, Germany).
Sequencing
Deletion breakpoints were analyzed by direct
sequencing of mtDNA fragments amplified by the
PCR reactions using an ABI 3700 capillary sequencer.
Sequences then were compared with a compre-
hensive mitochondrial databank.
Statistical analysis
Qualitative variables were compared by Fisher’s
exact probability test. A P value of less than 0.05
was considered to indicate a statistically significant
difference.
Results
In the last decade, mtDNA mutations have been
reported to be associated with development and
progression of colorectal cancer, which is probably the
most studied cancer type in the mitochondrial field.
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Figure 1. Diagram shows primers and their position on mtDNA
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It has also been reported that mitochondria are
the site of initiation of apoptosis; therefore,
mutation of its genome may play a causative role
in cancer.
Moreover, another report showed that 70% of
colon cancers examined displayed mitochondrial
DNA mutations [27].
The percentage of deleted 8.7 kb in our colon
cancer patients was 12.2%, which means this
deletion was observed in 11 patients out of 90.
Recently an 8.9 kb deletion in gastric cancer was
also reported [28]. We found a ~5 kb deletion in 
2 of our patients (Figure 2). These deletions in CRC
patients may result in multiple respiratory chain
deficiencies [29].
In the case of 8.7 kb deletion, the repeat
sequence flanking the deletion breakpoint was
confirmed in some samples by sequencing. It was
a 9-bp direct repeat (CTACTCCTA) in
5472/5481–14131/14140 and the deletion breakpoint
was between nucleotide positions (np) 5472 and
14140 (Figures 3A, 3B). The deleted and control band
are shown in Figure 4. The overall characteristics of
90 colon cancer patients with different deletions
are summarized in Table I.
Discussion
Deletion of ~8.7 kb causes a loss or truncation
of the structural genes of ATPase 6/8, COIII, ND3,
ND4L, ND4, ND5, ND6, Cytb and eight tRNA genes.
Defective respiratory enzymes containing protein
A
B
Figure 3. A – part of human mtDNA sequence. Denotation shows 9 bp directed repeat in 5472/5481–14131/14140. 





Figure 2. Detection of ~5 kb deletion in colon cancer
by multiplex PCR
Table I. Characteristics of 90 colorectal cancer patients
and frequency of the different deletions in them
n Frequency Frequency 
of ~8.7 kb of ~5 kb 
deletion deletion
Patients 90 11 2
Controls 33 0 0
P value 0.035* 1
Age [years]:
• ≥50 64 9 2
• <50 26 2 0
Sex:
• male 44 6 0
• female 46 5 2
*Significant
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subunits encoded by the deleted mtDNA may
further enhance free radical production, resulting
in more profound oxidative damage in patients.
Beside the above fact, we know that the copy
number of mtDNA is very high in cells and the
consequences of deletion would be apparent when
the deletion reached the threshold point.
In the presence of mtDNA deletions, which may
be caused as mentioned by ROS or free radicals
generated during aerobic metabolism, sensitive cells
are deprived of ATP (due to the defective respiratory
functions of mitochondria) and then they run into
a state of energy crisis through a ‘vicious cycle’ as
proposed by Wei [30]. This ‘vicious cycle’ may have
catastrophic consequences and is accelerated by
electron leakage from defective mitochondria; as
such, it may play an important role in the
pathophysiology of colorectal cancer patients.
Defective respiratory enzymes containing protein
subunits encoded by the deleted mtDNA may
further enhance free radical production, resulting
in more profound oxidative damage in CRC patients.
Since deletion in mtDNA is a sporadic event it could
confirm the probable association between deletions
in mtDNA and occurrence of colon cancer. As we
demonstrate in Table I we did not find 8.7 kb
deletions in our control subjects, which means that
8.7 kb deletions occur significantly more often in
colon cancer patients than in the normal
population.
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